Q1 EPS Forecast for Definium Therapeutics Cut by Analyst

Key Points

• HC Wainwright trimmed near‑term estimates — lowering Q1 2026 EPS to ($0.46) (from ($0.38)) and cutting FY2026/FY2027 — but kept a Buy rating with a lofty $70 price target while materially raising long‑range EPS forecasts (FY2029 $3.24, FY2030 $5.32).
• The analyst consensus is an average Buy with a mean price target of $35.70, while Definium shares trade around $17.76 (1‑year range $4.70–$18.70), implying significant upside to the street target.
• Definium is a clinical‑stage biopharma (formerly Mind Medicine) with lead candidates MM120 in Phase 3 for GAD/ADHD and DT402 in Phase 2a for autism, which supports the firm's multi‑year growth thesis.

Definium Therapeutics, Inc. (NASDAQ:DFTX - Free Report) - Equities research analysts at HC Wainwright lowered their Q1 2026 earnings per share estimates for shares of Definium Therapeutics in a research note issued to investors on Monday, March 2nd. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of ($0.46) for the quarter, down from their prior estimate of ($0.38). HC Wainwright has a "Buy" rating and a $70.00 price objective on the stock. The consensus estimate for Definium Therapeutics' current full-year earnings is ($1.35) per share. HC Wainwright also issued estimates for Definium Therapeutics' Q2 2026 earnings at ($0.46) EPS, Q3 2026 earnings at ($0.46) EPS, Q4 2026 earnings at ($0.46) EPS, FY2026 earnings at ($1.83) EPS, FY2027 earnings at ($1.52) EPS, FY2028 earnings at $0.72 EPS, FY2029 earnings at $3.24 EPS and FY2030 earnings at $5.32 EPS.

Several other research analysts have also weighed in on DFTX. Jefferies Financial Group started coverage on Definium Therapeutics in a research report on Thursday, January 29th. They issued a "buy" rating and a $30.00 target price on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Definium Therapeutics in a research note on Monday, February 2nd. Robert W. Baird set a $37.00 price target on shares of Definium Therapeutics in a report on Thursday, January 29th. Needham & Company LLC reaffirmed a "buy" rating on shares of Definium Therapeutics in a research report on Monday, January 5th. Finally, Chardan Capital raised shares of Definium Therapeutics to a "strong-buy" rating in a research report on Wednesday, November 19th. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $35.70.

Definium Therapeutics Price Performance

Definium Therapeutics stock opened at $17.76 on Thursday. Definium Therapeutics has a 1 year low of $4.70 and a 1 year high of $18.70. The company has a debt-to-equity ratio of 0.12, a quick ratio of 6.29 and a current ratio of 6.29. The firm has a 50 day moving average price of $15.90 and a 200 day moving average price of $12.99. The company has a market cap of $1.75 billion, a price-to-earnings ratio of -8.34 and a beta of 2.56.

Hedge Funds Weigh In On Definium Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Russell Investments Group Ltd. grew its stake in Definium Therapeutics by 110.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company's stock worth $25,000 after buying an additional 2,003 shares during the last quarter. BIT Capital GmbH bought a new stake in Definium Therapeutics in the 3rd quarter valued at about $26,000. CWM LLC boosted its stake in Definium Therapeutics by 67.4% during the 2nd quarter. CWM LLC now owns 4,459 shares of the company's stock valued at $29,000 after purchasing an additional 1,796 shares during the period. Fifth Third Bancorp grew its position in Definium Therapeutics by 5,593.2% in the 3rd quarter. Fifth Third Bancorp now owns 3,359 shares of the company's stock worth $40,000 after purchasing an additional 3,300 shares during the last quarter. Finally, Sound Income Strategies LLC bought a new stake in shares of Definium Therapeutics during the third quarter valued at approximately $46,000. 27.91% of the stock is owned by institutional investors.

Insider Transactions at Definium Therapeutics

In other Definium Therapeutics news, insider Mark Sullivan sold 11,276 shares of Definium Therapeutics stock in a transaction on Friday, December 26th. The shares were sold at an average price of $13.15, for a total value of $148,279.40. Following the completion of the transaction, the insider owned 282,576 shares of the company's stock, valued at $3,715,874.40. The trade was a 3.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Daniel Karlin sold 5,600 shares of the stock in a transaction on Friday, December 26th. The stock was sold at an average price of $13.15, for a total transaction of $73,640.00. Following the sale, the insider directly owned 425,025 shares in the company, valued at $5,589,078.75. This trade represents a 1.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 42,667 shares of company stock valued at $561,071. Insiders own 2.26% of the company's stock.

Key Definium Therapeutics News

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: HC Wainwright retained a "Buy" rating and a $70 price target and materially raised long‑range earnings power (FY2028–FY2030 upgrades, including FY2029 to $3.24 and FY2030 to $5.32), supporting a bullish, multi‑year thesis for DFTX. HC Wainwright Forecasts Strong Price Appreciation for Definium Therapeutics NASDAQ: DFTX Stock
• Neutral Sentiment: Reported short‑interest figures for early March were effectively zero/invalid (0 shares and NaN), so there is no clear short‑squeeze pressure or bearish positioning signal to interpret from that data.
• Negative Sentiment: HC Wainwright trimmed near‑term EPS forecasts across Q1–Q4 2026 (each to ($0.46) from ($0.38)) and lowered FY2026 to ($1.83) and FY2027 to ($1.52), indicating weaker near‑term profitability than previously expected — a potential headwind if guidance or operational updates confirm the slower short‑term trajectory.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.